TP53 and cancer: Because p53-mediated cell death causes hematologic and other acute radiation and chemotherapy toxicities, temporarily blocking p53 during genotoxic therapies for patients with p53-mutant tumors has been proposed as a viable approach to prevent acute side effects of cancer therapy (1, 2).